Analysis of Counterfeit Medicines and Adulterated Dietary Supplements by NMR
Myriam Malet-Martino
Université Paul Sabatier, Toulouse, France
Search for more papers by this authorMyriam Malet-Martino
Université Paul Sabatier, Toulouse, France
Search for more papers by this authorAbstract
The proliferation of counterfeit and poor-quality medicines is a major public health problem, especially in developing countries lacking adequate resources to effectively monitor their prevalence. Industrialized countries are, for the moment, more affected by the phenomenon of adulteration of dietary supplements (DS) and herbal drugs. Counterfeit medicines (CM) and adulterated DS, in addition to the serious health risk they pose to populations, constitute a major challenge for analytical laboratories for their detection and characterization. Although seldom used in quality control laboratories, NMR is a technique of choice to analyze complex mixtures and to determine their different constituents. The aim of this article is to present several examples of the use of 1H NMR as a first-line analytical technique for uncovering CM and adulterated DS. Studies on the quality evaluation of heparin, essential antimalarial medicines, drugs and DS intended to treat erectile dysfunction, slimming DS, anti-inflammatory DS, and some cosmetic creams are reviewed. The potential of isotopic NMR in the field of drug counterfeiting is also presented. Advantages and limitations of NMR are finally discussed.
References
- 1 Interpol, Thousands of illicit online pharmacies shut down in the largest-ever global operation targeting fake medicines, 2014. http://www.interpol.int/News-and-media/News/2014/N2014-089.
- 2 T. K. Mackey and B. A. Liang, BMC Med., 2013, 11, 233.
- 3 A. Attaran, D. Barry, S. Basheer, R. Bate, D. Benton, J. Chauvin, L. Garrett, I. Kickbusch, J. C. Kohler, K. Midha, P. N. Newton, S. Nishtar, P. Orhii, and M. McKee, BMJ, 2012, 345, e7381.
- 4 World Health Organization, WHO's role in the prevention and control of medical products of compromised quality, safety and efficacy such as substandard/spurious/falsely labelled/falsified/counterfeit medical products, 2011. http://apps.who.int/gb/ssffc/pdf_files/A_SSFFC_WG2_3-en.pdf.
- 5 World Health Organization, Medicines: spurious/falsely-labelled/falsified/ counterfeit (SFFC) medicines, Fact sheet n°275, 2012. http://www.who.int/mediacentre/factsheets/fs275/fr/.
- 6 World Health Organization, Guidelines for the development of measures to combat counterfeit drugs, 1999. http://www.who.int/medicines/publications/counterfeitguidelines/en/.
- 7 World Health Organization, Bull. World Health Org., 2010, 88, 247.
- 8 R. L. Bailey, J. J. Gahche, P. E. Miller, P. R. Thomas, and J. T. Dwyer, JAMA Intern. Med., 2013, 173, 355.
- 9 newhope, 2014 Global Supplement and Nutrition Industry Report. http://newhope360.com/2014-global-supplement-and-nutrition-industry-report.
- 10 A. Petroczi, G. Taylor, and D. P. Naughton, Food Chem. Toxicol., 2011, 49, 393.
- 11 M. Nuccitelli, Bodybuilding supplements, male enhancement and weight loss diet pills tainted, 2011. http://www.amazines.com/view_author.cfm?authorid=327961.
- 12 Z. Harel, S. Harel, R. Wald, M. Mamdani, and C. M. Bell, JAMA Intern. Med., 2013, 173, 926.
- 13 K. Dégardin, Y. Roggo, and P. Margot, J. Pharm. Biomed. Anal., 2014, 87, 167.
- 14 R. Martino, M. Malet-Martino, V. Gilard, and S. Balayssac, Anal. Bioanal. Chem., 2010, 398, 77.
- 15 Counterfeit Medicines: Volume II: Detection, Identification and Analysis, eds P. G. Wang and A. I. Wertheimer, ILM Publications: Hertfordshire, UK, 2012.
- 16 Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Countering the Problem of Falsified and Substandard Drugs, eds L. O. Gostin and G. J. Buckley, The National Academies: Washington, DC, 2013, 255.
- 17 S. Kovacs, S. E. Hawes, S. N. Maley, E. Mosites, L. Wong, and A. Stergachis, PLoS ONE, 2014, 9, e90601.
- 18 S. Beni, J. F. K. Limtiaco, and C. K. Larive, Anal. Bioanal. Chem., 2011, 399, 527.
- 19 M. Guerrini, Z. Zhang, Z. Shriver, A. Naggi, S. Masuko, R. Langer, B. Casu, R. J. Linhardt, G. Torri, and R. Sasisekharan, Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 16956.
- 20 M. Guerrini, D. Beccati, Z. Shriver, A. Naggi, K. Viswanathan, A. Bisio, I. Capila, J. C. Lansing, S. Guglieri, B. Fraser, A. Al-Hakim, N. S. Gunay, Z. Zhang, L. Robinson, L. Buhse, M. Nasr, J. Woodcock, R. Langer, G. Venkataraman, R. J. Linhardt, B. Casu, G. Torri, and R. Sasisekharan, Nat. Biotechnol., 2008, 26, 669.
- 21 T. Beyer, M. Matz, D. Brinz, O. Rädler, B. Wolf, J. Norwig, K. Baumann, S. Alban, and U. Holzgrabe, Eur. J. Pharm. Sci., 2010, 40, 297.
- 22 D. A. Keire, H. Ye, M. L. Trehy, W. Ye, R. E. Kolinski, B. J. Westenberger, L. F. Buhse, M. Nasr, and A. Al-Hakim, Anal. Bioanal. Chem., 2011, 399, 581.
- 23 D. A. Keire, D. J. Mans, H. Ye, R. E. Kolinski, and L. F. Buhse, J. Pharm. Biomed. Anal., 2010, 52, 656.
- 24 Q. Zang, D. A. Keire, R. D. Wood, L. F. Buhse, C. M. Moore, M. Nasr, A. Al-Hakim, M. L. Trehy, and W. J. Welsh, Anal. Chem., 2011, 83, 1030.
- 25 G. M. L. Nayyar, J. G. Breman, P. N. Newton, and J. Herrington, Lancet Infect. Dis., 2012, 12, 488.
- 26 N. Ranieri, P. Tabernero, M. D. Green, L. Verbois, J. Herrington, E. Sampson, R. D. Satzger, C. Phonlavong, K. Thao, P. N. Newton, and M. R. Witkowski, Am. J. Trop. Med. Hyg., 2014, DOI: 10.4269/ajtmh.13-0644.
- 27 E. Y. Klein, I. A. Lewis, C. Jung, M. Llinas, and S. A. Levin, Malar. J., 2012, 11, 110.
- 28 L. Nyadong, G. A. Harris, S. Balayssac, A. S. Galhena, M. Malet-Martino, R. Martino, R. M. Parry, M. D. Wang, F. M. Fernández, and V. Gilard, Anal. Chem., 2009, 81, 4803.
- 29 J. Barras, D. Murnane, K. Althoefer, S. Assi, M. D. Rowe, I. J. F. Poplett, G. Kyriakidou, and J. A. S. Smith, Anal. Chem., 2013, 85, 2746.
- 30 B. J. Venhuis and D. de Kaste, J. Pharm. Biomed. Anal., 2012, 69, 196.
- 31 D. N. Patel, L. Li, C. L. Kee, X. Ge, M. Y. Low, and H. L. Koh, J. Pharm. Biomed. Anal., 2014, 87, 176.
- 32 V. Gilard, S. Balayssac, A. Tinaugus, N. Martins, R. Martino, M. Malet-Martino 2015 J. Pharm. Biomed. Anal., 102, 476.
- 33 S. Trefi, C. Routaboul, S. Hamieh, V. Gilard, M. Malet-Martino, and R. Martino, J. Pharm. Biomed. Anal., 2008, 47, 103.
- 34 S. Trefi, V. Gilard, S. Balayssac, M. Malet-Martino, and R. Martino, Magn. Reson. Chem., 2009, 47, 5163.
- 35 C. L. Kee, H. L. Koh, B. C. Bloodworth, Y. Zeng, K. H. Kiang, M. Y. Low, and X. Ge, J. Pharm. Biomed. Anal., 2014, 98, 153 and references quoted in.
- 36 World Health Organization, Obesity and Overweight, Fact Sheet n°311, 2014. http://www.who.int/mediacentre/factsheets/fs311/en/.
- 37 L. M. de Carvalho, M. Martini, A. P. Moreira, A. P. de Lima, D. Correia, T. Falcão, S. C. Garcia, A. V. de Bairros, P. C. do Nascimento, and D. Bohrer, Forensic Sci. Int., 2011, 204, 6.
- 38 F. Song, D. Monroe, A. El-Demerdash, and C. Palmer, J. Pharm. Biomed. Anal., 2014, 88, 136.
- 39 J. Vaysse, S. Balayssac, V. Gilard, D. Desoubdzanne, M. Malet-Martino, and R. Martino, Food Addit. Contam., 2010, 27, 903.
- 40 Y. B. Monakhova, T. Kuballa, S. Löbell-Behrends, S. Maixner, M. Kohl-Himmelseher, W. Ruge, and D. W. Lachenmeier, Drug Test. Anal., 2013, 5, 400.
- 41 M. Johansson, D. Fransson, T. Rundlöf, N. H. Huynh, and T. Arvidsson, J. Pharm. Biomed. Anal., 2014, 100, 215.
- 42 R. Hachem, M. Malet-Martino, and V. Gilard, J. Pharm. Biomed. Anal., 2014, 98, 94.
- 43 L. M. A. Silva, E. G. A. Filho, S. S. Thomasi, B. F. Silva, A. G. Ferreira, and T. Venâncio, Magn. Reson. Chem., 2013, 51, 541.
- 44 J. Wiest, C. Schollmayer, G. Gresser, and U. Holzgrabe, J. Pharm. Biomed. Anal., 2014, 97, 44.
- 45 I. McEwen, A. Elmsjö, A. Lehnström, B. Hakkarainen, and M. Johansson, J. Pharm. Biomed. Anal., 2012, 70, 245.
- 46 E. Deconinck, A. M. van Nederkassel, I. Stanimirova, M. Daszykowski, F. Bensaid, M. Lees, G. J. Martin, J. R. Desmurs, J. Smeyers-Verbeke, and Y. V. Heyden, J. Pharm. Biomed. Anal., 2008, 48, 27.
- 47 D. Acetti, E. Brenna, G. Fronza, and C. Fuganti, Talanta, 2008, 76, 651.
- 48 E. Brenna, G. Fronza, and C. Fuganti, Anal. Chim. Acta, 2007, 601, 234.
- 49 V. Silvestre, V. Maroga Mboula, C. Jouitteau, S. Akoka, R. J. Robins, and G. S. Remaud, J. Pharm. Biomed. Anal., 2009, 50, 336.
- 50 U. Bussy, C. Thibaudeau, F. Thomas, J. R. Desmurs, E. Jamin, G. S. Remaud, V. Silvestre, and S. Akoka, Talanta, 2011, 85, 1809.
- 51 G. S. Remaud, U. Bussy, M. Lees, F. Thomas, J. R. Desmurs, E. Jamin, V. Silvestre, and S. Akoka, Eur. J. Pharm. Sci., 2013, 48, 464.
- 52 G. Pagès, A. Gerdova, D. Williamson, V. Gilard, R. Martino, and M. Malet-Martino, Anal. Chem., 2014, 86, 11897.
Citing Literature
Browse other articles of this reference work: